Karen Carty

2.5k total citations
18 papers, 381 citations indexed

About

Karen Carty is a scholar working on Reproductive Medicine, Pulmonary and Respiratory Medicine and Obstetrics and Gynecology. According to data from OpenAlex, Karen Carty has authored 18 papers receiving a total of 381 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Reproductive Medicine, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Obstetrics and Gynecology. Recurrent topics in Karen Carty's work include Ovarian cancer diagnosis and treatment (9 papers), Endometrial and Cervical Cancer Treatments (6 papers) and Genomics and Phylogenetic Studies (3 papers). Karen Carty is often cited by papers focused on Ovarian cancer diagnosis and treatment (9 papers), Endometrial and Cervical Cancer Treatments (6 papers) and Genomics and Phylogenetic Studies (3 papers). Karen Carty collaborates with scholars based in United Kingdom, France and Australia. Karen Carty's co-authors include Luca Ermini, Yoshinori Fukasawa, Hai Wang, James Paul, Susana Banerjee, Hani Gabra, Charlie Gourley, P. Vasey, Rosemary Lord and S.E. Davidson and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Karen Carty

18 papers receiving 379 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karen Carty United Kingdom	9	148	122	92	91	54	18	381
Asli Bahadirli-Talbott United States	11	173 1.2×	197 1.6×	98 1.1×	101 1.1×	62 1.1×	12	533
Michael Ruvolo United States	8	239 1.6×	110 0.9×	52 0.6×	35 0.4×	39 0.7×	10	449
Laurent Galio France	12	351 2.4×	129 1.1×	42 0.5×	81 0.9×	52 1.0×	20	772
Ming-quan Su China	9	189 1.3×	11 0.1×	72 0.8×	12 0.1×	16 0.3×	23	319
Lihong Bian China	9	236 1.6×	44 0.4×	31 0.3×	21 0.2×	6 0.1×	23	441
Xiancheng Zeng China	13	308 2.1×	10 0.1×	38 0.4×	10 0.1×	17 0.3×	20	506
P. Jurka Poland	10	230 1.6×	30 0.2×	108 1.2×	5 0.1×	31 0.6×	48	541
Min‐Min Yuan China	12	75 0.5×	134 1.1×	72 0.8×	197 2.2×	7 0.1×	21	578
Sarah Ariansen Norway	13	170 1.1×	11 0.1×	147 1.6×	6 0.1×	90 1.7×	23	472
Anthony L. Scarman Australia	9	96 0.6×	81 0.7×	36 0.4×	6 0.1×	4 0.1×	10	362

Countries citing papers authored by Karen Carty

Since Specialization

Citations

This map shows the geographic impact of Karen Carty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Carty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Carty more than expected).

Fields of papers citing papers by Karen Carty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Carty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Carty. The network helps show where Karen Carty may publish in the future.

Co-authorship network of co-authors of Karen Carty

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Carty. A scholar is included among the top collaborators of Karen Carty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Carty. Karen Carty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

1.

Fukasawa, Yoshinori, Patrick Driguez, Salim Bougouffa, et al.. (2024). Plasticity of repetitive sequences demonstrated by the complete mitochondrial genome of Eucalyptus camaldulensis. Frontiers in Plant Science. 15. 1339594–1339594. 2 indexed citations

2.

Wasan, Harpreet, Jiazhao Wang, Elaine McCartney, et al.. (2023). LBA100 CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes. Annals of Oncology. 34. S1339–S1339. 2 indexed citations

3.

Glasspool, Rosalind, Caroline Kelly, Liz-Anne Lewsley, et al.. (2023). CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. Cancers. 15(6). 1823–1823. 8 indexed citations

4.

Friedländer, Michael, Charlotte Benson, Rachel O’Connell, et al.. (2021). Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology. 161(1). 160–165. 8 indexed citations

5.

Driguez, Patrick, Salim Bougouffa, Karen Carty, et al.. (2021). LeafGo: Leaf to Genome, a quick workflow to produce high-quality de novo plant genomes using long-read sequencing technology. Genome biology. 22(1). 256–256. 22 indexed citations

6.

Edmondson, Richard J., Rachel O’Connell, Susana Banerjee, et al.. (2021). Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology. 163(3). 524–530. 12 indexed citations

7.

Fukasawa, Yoshinori, et al.. (2020). LongQC: A Quality Control Tool for Third Generation Sequencing Long Read Data. G3 Genes Genomes Genetics. 10(4). 1193–1196. 115 indexed citations

8.

Gershenson, David M., Austin Miller, William E. Brady, et al.. (2019). A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer. Annals of Oncology. 30. v897–v898. 42 indexed citations

9.

Zhou, Cong, Sarah Taylor, Jonathan Tugwood, et al.. (2019). Dynamics of circulating vascular endothelial growth factor‐A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology. 85(8). 1781–1789. 3 indexed citations

10.

Symonds, R.P., Charlie Gourley, S.E. Davidson, et al.. (2015). Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Oncology. 16(15). 1515–1524. 84 indexed citations

11.

Symonds, Paul, Charlie Gourley, S.E. Davidson, et al.. (2014). Circca: a Randomised Double Blind Phase Ii Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer. (Cruk Grant Ref: C1256/A11416). Annals of Oncology. 25. v1–v1. 7 indexed citations

12.

O’Cathail, Séan M., Sarah Mahmoud, Karen Carty, et al.. (2013). Intravenous Versus Oral Dexamethasone Premedication in Preventing Paclitaxel Infusion Hypersensitivity Reactions in Gynecological Malignancies. International Journal of Gynecological Cancer. 23(7). 1318–1325. 14 indexed citations

13.

Agarwal, Roshan, Charlie Gourley, Timothy Perren, et al.. (2010). First-line therapy for ovarian cancer with carboplatin followed by paclitaxel–gemcitabine (SCOTROC5): A feasibility study and comparative analysis of the SCOTROC series. European Journal of Cancer. 46(11). 2020–2026. 3 indexed citations

14.

Vasey, P., Richard H. Wilson, Gordon Rustin, et al.. (2008). A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. British Journal of Cancer. 98(11). 1774–1780. 34 indexed citations

15.

Vasey, P., James Paul, G.J.S. Rustin, et al.. (2007). Maintenance erlotinib (E) following first-line treatment with docetaxel, carboplatin and erlotinib in patients with ovarian carcinoma. Journal of Clinical Oncology. 25(18_suppl). 5560–5560. 5 indexed citations

16.

Crawford, S. M., James Paul, N.S. Reed, et al.. (2004). The prognostic significance of the CA125 nadir in patients that achieve a CA125 response. Journal of Clinical Oncology. 22(14_suppl). 5001–5001. 6 indexed citations

17.

Crawford, S. M., James Paul, N.S. Reed, et al.. (2004). The prognostic significance of the CA125 nadir in patients that achieve a CA125 response. Journal of Clinical Oncology. 22(14_suppl). 5001–5001. 4 indexed citations

18.

Vasey, P., S.B. Kaye, James Paul, et al.. (2004). A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers. Journal of Clinical Oncology. 22(14_suppl). 5017–5017. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact